The Global Immuno-oncology Therapeutics Market—Adoptive T-cell Therapies, Forecast to 2022

The Next Generation of Cancer Therapies

USD 3,000.00

* Required Fields

USD 3,000.00

PAY BY INVOICE

Be the first to review this product

Immuno-oncology refers to drugs that are used to stimulate the human immune system to target the fight against cancer. The immune system is capable of recognizing and eliminating foreign substances, including tumor cells. Tumors have, however, been able to escape detection by the immune system. There are drugs that can empower the immune system cells to attack tumor cells. Natural Killer (NK) cells are the main cells involved in the natural immune response. Once an immune response is initiated, the immune response can be sustained through memory, called adaptive immunity. Cytotoxic T cells are the main cells involved with adaptive immunity. The anti-cancer activity of NK cells and cytotoxic T cells is done thro

Key Issues Addressed

  • What adoptive T-cell (CAR-T & TCR) therapies are in development and for what indications?
  • What products and indications will be launched in the next 7 years?
  • Who is investing in the development of adoptive T-cell therapies, at what phase, and at what level of deal funding?
  • What are some of the cost implications for adoptive T-cell therapies, especially when combined with other immuno-oncology therapies?
  • What are the challenges to development and commercialization of adoptive T-cell therapies?
  • What challenges do payors face related to the high cost of specialty therapeutics?

Table of Contents

Executive Summary to the Adoptive T-cell Therapeutics MarketKey TakeawayScope and SegmentationKey Questions this Study will AnswerExecutive Summary—Market SnapshotExecutive Summary—Market Snapshot (continued)8 Big Market Themes for Immuno-oncology TherapiesHematological Cancers Dominate the PipelineGame Changing Companies Investors Pour in Significant FundsKey 2017 Predictions—Adoptive T-cell Therapy MarketDisruptive Pipeline AnalysisKey MethodologyAdoptive T-cell Therapy Drug ClassesTimeline of Adoptive T-cell Product EvolutionTimeline of Adoptive Immuno-oncology Product ApprovalsCompetitive LandscapeCompetitive Landscape—Target SegmentsCompetitive Landscape—Target Product CountsAdoptive T-cell Therapy Segmentation Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells)Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells) (continued)Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells) CRCompetitive Landscape—T-cell Receptor (TCR) SegmentProduct Dashboards of Leading Adoptive T-cell TherapiesCAR-T Product DashboardCAR-T Product Dashboard (continued)TCR Product DashboardCommercialization Analysis Opportunities in this MarketChallenges for this MarketPotential Game Changing Immuno-oncology TherapiesOverall Environmental Impact FactorsImmuno-oncology Area Product Patent ExpirationsCommercialization Analysis—BiomarkersAntigen TargetsCommercialization Analysis—Cost ConsiderationsOpportunities in this Market—Escalating Drug CostsAdoptive T-cell Therapy Payor EnvironmentJ-Codes, Annual Costs and US PayorsAdoptive T-cell Therapies—On-Label Reimbursement PathReimbursement Pathway—Off-Label: MedicareReimbursement Pathway—Off-Label: Commercial PayorsReimbursement Pathway—Off-Label: Commercial Payors (continued)A Snapshot of Global Drug Price Control Methods Pitfalls to AvoidCommercialization Analysis—Key Companies and Products to WatchCompanies to WatchCompanies to Watch (continued)Adoptive T-cell Therapy Forecast—2022 ($3.9 Billion) Forecasts by ProductCommercialization Analysis—Funding ConsiderationsImmuno-oncology MilestonesImmuno-oncology Milestones (continued)Deal and Financing—Adoptive T-cell TherapiesDeal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued) Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Deal and Financing—Adoptive T-cell Therapies (continued)Conclusion and Future OutlookKey ConclusionsNew Market Opportunities—Adoptive T-cell TherapiesThe Last Word—3 Big PredictionsLegal DisclaimerAppendix—CAR-T Therapies Development Pipeline SummariesPipeline Analysis—CAR-T Segment, Products in DevelopmentPipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Pipeline Analysis—CAR-T Segment, Products in Development (continued)Appendix—T-cell Receptor Therapies: Development Pipeline SummaryPipeline Analysis—T-cell Receptor Segment, Products in DevelopmentPipeline Analysis—T-cell Receptor Segment, Products in Development (continued)Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)List of ExhibitsList of Exhibits (continued)List of Exhibits (continued)List of Exhibits (continued)The Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition—Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation Excellence

Infographic





Keyword1

Keyword2

Keyword3

Related Research

Release Date : 18-Apr-18

Region : North America

Release Date : 09-Apr-18

Region : North America

Release Date : 14-Mar-18

Region : North America

Release Date : 14-Mar-18

Region : North America

Release Date : 09-Jan-18

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.